University of Colorado Cancer Center
The University of Colorado Cancer Center at Denver & Health Sciences Center in Aurora has established itself as a leader in excellent cancer treatment in the region.
Its numerous and contemporary technology enable exceptional research, timely diagnosis, and a plethora of treatment plans tailored to the individual needs of each patient’s affliction. Although the institution treats all cancers aggressively, diseases of the neck and lungs are of particular specialty.
A reputable organization, the National Institutes of Health has deemed UCCC a Comprehensive Cancer Center for routinely exhibiting a strong commitment and high standard of excellence in cancer prevention, advanced research, education, and patient care since its establishment in 1985.
The U-C Anschutz Medical Campus is the mecca for cancer related developmental research and innovative treatment. For this reason, many prestigious universities, such as Colorado State University, openly collaborate to produce some of the greatest recent findings in cancer related research. Some of them include groundbreaking advanced in detection methods and therapy guided by biomarkers. The study of genealogy in relation to cancer’s growth is another area of focus and advancement.
The facility is blessed with the expertise of over 50 associated, all with the cooperative goal of treating respiratory cancers, such as mesothelioma. All forms of cancers are treated at the center, while the research and understanding of lung cancer, the most fatal form of cancer, is the primary focus.
The program actively encourages the collaborative efforts from the wide variety of medical specialists, such as pathologists and oncologists, for optimal effectiveness of research and treatment. Dr. Xiao-Jing Wang, a world renowned head cancer specialist, and Dr. York Miller, lung cancer specialist, continue to lead the program, upholding its strong reputation.
As research spearheads the everyday lives of the faculty, clinical, translational, and behavioral research is a constant. This has led to collaborations with over a dozen lung cancer programs around the United States with their collective focus on noticing similarities between cancers and designing clinical trials with that insight. Patients are deeply encouraged to become involved with their voluntary clinical studies.
Lung cancer remains one of the most elusive diseases to cure. The LHN has become a stronghold for both traditional means of treatment, including chemotherapy, and well tested experimental therapies.
Many of these therapeutic means have had continued success in relieving patients of their afflictions. The ALK Inhibitor is at the forefront of these treatments, as it is able to inhibit a gene closely associated in those with lung cancer. Still under rigorous study, this drug is believed to be able to reduce the size of tumors and alleviate the need for traditional treatments like radiation.